Canos
AI-powered blood test to detect cancer in dogs (and cats soon).
Canos is bringing a human-grade liquid biopsy platform for dogs, starting with a single blood draw. We sequence cell-free DNA to perform multi-modal analysis of fragmentation, copy number variation, native methylation (5mC and 5hmC) and more to detect cancer signals. Owners bank a healthy baseline for their dog and track changes every year. Dogs already diagnosed get personalized monitoring through treatment. We partner with mobile vets and vet clinics to serve SF and NYC. Our mission is to make pet cancer curable through early detection and monitoring.
- Website
- canos.ai
- City
- Oxford
- Country
- United Kingdom
- YC batch
- Fall 2026
- Stage
- Early stage
- AI-native
- Yes
More Health & bio in Oxford
Sensible Biotechnologies
Unlocking the next generation of mRNA medicines
FinalDose
Programmable DNA drug destroying all cancers, unlocking 80% of targets
Evolvere BioSciences
Making Next-Generation Antibiotics that Outpace Bacterial Evolution
Blue Earth Therapeutics
Advancing next generation targeted radiopharmaceuticals to treat patients who have cancer.
Synox Therapeutics UK
At SynOx Therapeutics, we are focused on improving the lives of people living with rare diseases. Learn more.
Claim this profile
Free and instant: prove you run canos.ai and edit the profile yourself.
- Your logo, office address and founder photos
- The ✓ Verified mark next to Canos across the site
- Open roles listed on the Hiring board
- A followed link back to your website
A rank card with Canos's standing on Labspie, or a simple badge. Both link to this profile and update themselves.
